The Lynx Group
Cholangiocarcinoma News

A Comprehensive Genomic and Immune Profiling Study of IDH1- and IDH2-Driven Intrahepatic CCA

2021 Year in Review: Cholangiocarcinoma — December 17, 2021

A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.

To define the genomic and immunologic profile of intrahepatic cholangiocarcinoma (iCCA) with IDH1/2 genetic alterations, biomarker analysis with comprehensive genomic profiling was performed in a large sample set; results of this study were reported at the 2021 American Society of Clinical Oncology Annual Meeting.

In this study, comprehensive genomic profiling was performed in 3067 patients with advanced-stage iCCA. Given the relationship between IDH mutations and homologous recombination defects, genomic loss of heterozygosity in IDH1/2-mutated cases, IDH wild-type, and BRCA-mutated iCCA were examined. The status of tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 expression in IDH-mutated and IDH wild-type iCCA was evaluated to identify potential biomarkers of immune checkpoint inhibition response. In 100 surgical samples from 96 patients, immunohistochemistry analysis was performed to assess densities of tumor-associated immune cells and immune checkpoint markers expressed in epithelial malignant cells and in the tumor microenvironment, to examine potential biomarkers for immunotherapy and to characterize the immune microenvironment of IDH1/2-altered iCCA.

Of the 3067 samples tested, 426 (14%) samples were IDH1-positive, 125 (4%) were IDH2-positive, and 2516 (82%) were IDH wild-type. The incidence of IDH1 and IDH2 alterations was found to be mutually exclusive. Furthermore, compared with IDH1/2 wild-type iCCA, there were significantly fewer co-occurring targetable genetic alterations in IDH1-positive and IDH2-positive iCCA, including FGFR2 rearrangements (P <.0001), ERBB2 amplifications/variants (P = .0009), TP53 (P <.0001), CDKN2A/CDKN2B (P <.0001), MTAP (P <.0001), and BRAF (P = .04). No significant difference in median genomic loss of heterozygosity was seen between IDH1-positive/IDH2-positive iCCA and IDH wild-type iCCA (P = .37).

Tumor samples with IDH wild-type iCCA showed a higher frequency of biomarkers of immune checkpoint inhibition response, including MSI-high, TMB >10 mut/Mb, and PD-L1 positivity, compared with IDH1-positive iCCA. In the samples from 96 surgical patients, 30% were positive for IDH1/2 mutation; however, no significant difference was observed between IDH1/2-mutated and IDH wild-type cohorts in the 14 immune biomarker panel expression.

These biomarker analyses reveal significant differences in genetic alterations between IDH-mutated and IDH wild-type iCCA, with no significant differences observed in immune biomarker expression and genomic loss of heterozygosity.

Source: Makawita S, Borad MJ, Carapeto F, et al. IDH1 and IDH2 driven intrahepatic cholangiocarcinoma (IHCC): a comprehensive genomic and immune profiling study. J Clin Oncol. 2021;39(suppl_15):4009-4009.

Related Items

Phase 1 Results of Gunagratinib in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations
2021 Year in Review: Cholangiocarcinoma
A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Prognostic Value of FGFR2 Alterations in Patients Receiving Systemic Chemotherapy for Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
FGFR2 Fusion and/or Rearrangement Profiling in Chinese Patients with Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
Characteristics of IDH Mutations in Bile Duct Carcinoma in a Chinese Population
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Silmitasertib (CX-4945) plus Gemcitabine and Cisplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic CCA
2021 Year in Review: Cholangiocarcinoma
Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Targeted Therapies in CCA: Assessment of US Oncologist Practice Patterns
2021 Year in Review: Cholangiocarcinoma
Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
First-Line Toripalimab plus Lenvatinib in Combination with GemOx Chemotherapy for Advanced Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Results of a phase 2 study indicate that toripalimab and lenvatinib in combination with GemOx chemotherapy provide antitumor activity and reasonable tolerability in patients with advanced intrahepatic CCA.
Comparative Landscape of Actionable Somatic Alterations in Advanced CCA from Circulating Tumor and Tissue-Based DNA Profiling
2021 Year in Review: Cholangiocarcinoma
Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation
By Loretta Fala
2021 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile duct that forms inside the liver (ie, intrahepatic) or outside the liver (ie, extrahepatic, including perihilar and distal tumors). Individuals with colitis or certain liver diseases may have an increased risk for CCA. Although the precise incidence of CCA is unknown, an estimated 8000 new cases of CCA are diagnosed annually in the United States. It is likely, however, that this number is higher, because CCA is difficult to diagnose and may be misclassified at times.
2021 Cholangiocarcinoma Year in Review
By Rachna T. Shroff, MD, MS
2021 Year in Review: Cholangiocarcinoma
This edition of Year in Review is focused on cholangiocarcinoma (CCA), which is a diverse group of malignancies characterized by genomic heterogeneity that potentially drives its pathogenesis. Below is a quick review of some of the topics discussed in this issue, with a focus on recent advances, potentially practice-changing developments, and ongoing challenges in CCA.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: